CGTLive’s Weekly Rewind – August 5, 2022

Article

Review top news and interview highlights from the week ending August 5, 2022.

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Allogeneic Cell Therapy Trial to Initiate in Ovarian Cancer

Avenge Bio previously presented positive preclinical data at the ASGCT 2022 meeting.

2. Craig M. McDonald, MD, on Safety and Efficacy of DMD Cell Therapy

The principal investigator of the HOPE-2 trial discussed safety and efficacy of Capricor’s CAP-1002.

3. REGENXBIO's MPSII Gene Therapy Charts Course to Approval

The FDA will consider RGX-121's BLA in an accelerated approval pathway.

4. IND Cleared for Dual-Targeted CAR T Therapy for B-Cell Malignancies

UCART2022 is an allogeneic therapy that targets both CD20 and CD22.

5. IND Halted for T-Cell Malignancy Multiplex-Edited Cell Therapy

Beam Therapeutics submitted an IND for BEAM-201 in June 2022.

Recent Videos
Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Steven W. Pipe, MD, a professor of pediatric hematology/oncology at CS Mott Children’s Hospital
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Related Content
© 2024 MJH Life Sciences

All rights reserved.